It was only a few weeks ago that IBM Watson (cognitive system) and Illumina (manufacturer of sequencing devices based on Next Generation Sequencing (NGS) technology) came out. In the context of the indication tumors an intensified co-operation is to arise. In addition to a very high sequencing capacity, NGS allows for the clonal sequencing of individual molecules, a higher diagnostic sensitivity by parallel sequencing of entire gene panels, simplified handling as well as the parallel and therefore more cost-effective processing of the samples. In other…Continue Reading “Next Generation Sequencing – Interdisciplinary cooperation MLL (Germany), IBM Watson (USA), Illumina (USA)”

Market overview of safe and reproducible purificationSample preparation in the laboratory with molecular biology


Do you need a proven insulation method based on magnetic bead technology?

Do you need a safe sample processing?

Looking for an easy-to-use Walk Away System?

Continue Reading "Market overview of safe and reproducible purification"

The research focus on pharmacogenomics and individualized medicine at the german BfArM is to investigate the extent to which the genetic predisposition contributes to how a specific patient responds to a drug. There are genetic influences on the breakdown of drugs in the body, metabolism (metabolism).Ultrasound metabolizers are significantly faster in drug use than most people. As a result, this group increases the risk that certain side effects occur or the therapeutic effect does not occur. In the case of poor metabolizers, which degrade the…Continue Reading “Pharmacogenomic diagnostics is part of the German innovation fund 2017”

VIGORIS HEALTHCARE has supported Dr. Seibt Genomics Bonn on the stand of Medica Düsseldorf. VIGORIS HEALTHCARE is the official consulting and sales partner of Dr. Seibt Genomics. Picture: Dietmar Bönsch, VIGORIS Partner North-West Why do we support Dr. Seibt Genomics? Dietmar Bönsch*): “Genetic tests, especially in the context of medicines, I regard as a future-oriented medicine for safe and promising drug therapy.” `*) Dietmar Bönsch is a health economist and has been a stranger to hospital management and statutory health insurance for decades. © 2016…Continue Reading “Genetic Impressions of the Medica Düsseldorf 2016”